Biosimilars Receive Positive News On Nov. 19, 2015, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for SB4, an etanercept biosimilar product that will be called Benepali.1 If approved, Benepali can be used to treat rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis and plaque psoriasis…. [Read More]
Etanercept Biosimilars A number of Phase 3 trials are ongoing for etanercept biosimilars.1 One evaluation identified three trials in rheumatoid arthritis (RA) patients and one in psoriasis patients. The psoriatic arthritis trial evaluated PASI as a primary endpoint and the following secondary endpoints: PASI50, PASI75, PASI90, PASI score, laboratory values, ECG, adverse events (AEs), injection… [Read More]
Biosimilars for etanercept and sarilumab are being examined in multiple Phase 3 trials for their effects in RA and psoriasis patients.... [Read More]
Clinical trials on rheumatology drugs, including sarilumab, show promise for patients with rheumatoid arthritis also taking methotrexate... [Read More]
Latest findings on rheumatological drug therapies, including methotrexate for RA, tumor necrosis factor inhibitors for SpA... [Read More]
Information on new approvals and medication safety that rheumatologists need to know... [Read More]
Rheumatology-related drug safety, approvals, and what’s in the pipeline.... [Read More]
Information on new approvals and medication safety... [Read More]